See the published version of this article at BMC Research Notes.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research note
Immunohistochemical expression of Cyclin D1 among Sudanese patients diagnosed with benign and malignant prostatic lesions
Nouh Saad Mohamed
National University - Sudan
Corresponding Author
ORCiD: https://orcid.org/0000-0001-6843-3361
License:
This work is licensed under a CC BY 4.0 License. Read Full License
View the published version at BMC Research Notes.
Objectives: Prostate cancer (PC) is common cancer worldwide. Several markers have been developed to differentiate between benign prostatic hyperplasia (BPH) from PC. A descriptive retrospective hospital-based study aimed at determining the expression of Cyclin D1 in BPH and PC. the study took place at different histopathology laboratories in Khartoum state, Sudan, from December 2016 to January 2019. Formalin-fixed paraffin-embedded blocks were sectioned and fixed in 3-aminopropyltriethoxysilane coated slides incubated into primary antibody for Cyclin D1. The assessment of immunoreactivity of Cyclin D1 of each section was done using the Gleason scoring system. Results: A total of 153 males’ prostate sections included in this study, of them, 120 (78.4%) were PC, and 33 (21.6%) were BPH. Their age ranged from 45 to 88 years, mean age was 66.19 ± 8.599. 142 (92.8%) did not have a family history of PC, while 11 (7.2%) patients reported having a family history. The Gleason scoring showed a total of 81 (52.9%) patients with high-grade and 39 (25.5%) with low-grade. 118 (97.5%) patients had PC showed positive results for Cyclin D1, while BPH was 3 (2.5%). P value < 0.001. Cyclin D1 staining was associated with high-grade Gleason score and perineural invasion, P value 0.001.
Keywords
Prostate cancer, Immunohistochemical expression, Prognostic markers, Cyclin D1
Figure 1
Figure 2
This is a list of supplementary files associated with this preprint. Click to download.
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
Version 2
Posted 06 Jan, 2020
Published
On 17 Jun, 2020
No community comments so far
Editorial decision: Accept
On 11 Jun, 2020
Reviewers invited
Invitations sent on 03 Feb, 2020
Editor assigned
On 02 Jan, 2020
Submission checks complete
On 01 Jan, 2020
Editor invited
On 01 Jan, 2020
No comments provided
Editorial decision: Minor revision
On 24 Dec, 2019
Review #1 received
Received 28 Nov, 2019
Reviewer #1 agreed
On 05 Jul, 2019
Submission checks complete
On 05 Jul, 2019
Editor invited
On 05 Jul, 2019
Editor assigned
On 05 Jul, 2019
Reviewers invited
Invitations sent on 05 Jul, 2019
First submitted
On 03 Jul, 2019
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Cancer Biology
Learn more about our company.
This preprint is under consideration at BMC Research Notes. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research note
Immunohistochemical expression of Cyclin D1 among Sudanese patients diagnosed with benign and malignant prostatic lesions
Nouh Saad Mohamed
National University - Sudan
Corresponding Author
ORCiD: https://orcid.org/0000-0001-6843-3361
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
Version 2
Posted 06 Jan, 2020
Published
On 17 Jun, 2020
No community comments so far
Editorial decision: Accept
On 11 Jun, 2020
Reviewers invited
Invitations sent on 03 Feb, 2020
Editor assigned
On 02 Jan, 2020
Submission checks complete
On 01 Jan, 2020
Editor invited
On 01 Jan, 2020
No comments provided
Editorial decision: Minor revision
On 24 Dec, 2019
Review #1 received
Received 28 Nov, 2019
Reviewer #1 agreed
On 05 Jul, 2019
Submission checks complete
On 05 Jul, 2019
Editor invited
On 05 Jul, 2019
Editor assigned
On 05 Jul, 2019
Reviewers invited
Invitations sent on 05 Jul, 2019
First submitted
On 03 Jul, 2019
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Cancer Biology
License:
This work is licensed under a CC BY 4.0 License. Read Full License
View the published version at BMC Research Notes.
Objectives: Prostate cancer (PC) is common cancer worldwide. Several markers have been developed to differentiate between benign prostatic hyperplasia (BPH) from PC. A descriptive retrospective hospital-based study aimed at determining the expression of Cyclin D1 in BPH and PC. the study took place at different histopathology laboratories in Khartoum state, Sudan, from December 2016 to January 2019. Formalin-fixed paraffin-embedded blocks were sectioned and fixed in 3-aminopropyltriethoxysilane coated slides incubated into primary antibody for Cyclin D1. The assessment of immunoreactivity of Cyclin D1 of each section was done using the Gleason scoring system. Results: A total of 153 males’ prostate sections included in this study, of them, 120 (78.4%) were PC, and 33 (21.6%) were BPH. Their age ranged from 45 to 88 years, mean age was 66.19 ± 8.599. 142 (92.8%) did not have a family history of PC, while 11 (7.2%) patients reported having a family history. The Gleason scoring showed a total of 81 (52.9%) patients with high-grade and 39 (25.5%) with low-grade. 118 (97.5%) patients had PC showed positive results for Cyclin D1, while BPH was 3 (2.5%). P value < 0.001. Cyclin D1 staining was associated with high-grade Gleason score and perineural invasion, P value 0.001.
Figure 1
Figure 2